| ¿µ¹® | deoxyribonucleic acid (DNA) | ÇÑ±Û | µ¥¿Á½Ã¸®º¸ÇÙ»ê |
|---|---|---|---|
| ¼³¸í | ÇÙ»êÀÇ ÀÏÁ¾À¸·Î DNA¶ó°íµµ ÇÑ´Ù. DeoxyribonucleotideÀÇ ÁßÇÕüÀ̸ç À¯ÀüÀÚÀÇ ÈÇÐÀû º»Ã¼ÀÌ´Ù. RNA¹ÙÀÌ·¯½º ÀÌ¿ÜÀÇ ¸ðµç »ý¹°Àº DNA¸¦ À¯ÀüÀÚ·Î Áö´Ï°í ÀÖ´Ù. µð¿Á½Ã¸®º¸´ºÅ¬·¹¿ÀƼµå(deoxyribonucleotide)´Â ¿°±â¿Í ´ç(2'-deoxy-D-ribose)°ú ÀλêÀ¸·Î ÀÌ·ç¾îÁø´Ù. ¿°±â´Â ¾Æµ¥´Ñ(adenine), ±¸¾Æ´Ñ(guanine), Ƽ¹Î(thymine)¹× ½ÃÅä½Å(cytosine)ÀÇ 4°¡ÁöÀ̸ç, À̰ÍÀº ´ç¿¡ ºÎÂøµÇ¾î ÀÖ´Ù. ÀÎ»ê ¿ª½Ã ´çÀÇ ÇÑ ºÎºÐ¿¡ ºÎÂøµÇ¾î ÀÖ´Ù. ÀÌ deoxyribonucleotideÀÇ ´çÀº ´Ù¸¥ deoxy- ribonucleotideÀÇ ´ç°ú ÀλêÀ» »çÀÌ¿¡ ³õ°í °áÇÕÀ» ÇÏ°Ô µÇ¾î ÇϳªÀÇ ±ä »ç½½À» Çü¼ºÇÏ°Ô µÈ´Ù. Áï ´ç°ú ÀλêÀÌ ÁÖÃàÀÌ µÇ¾î¼ deoxyribonucleotideÀÇ ±ä »ç½½À» ¸¸µç´Ù. ÀÌ deoxyribonucleotideÀÇ »ç½½ µÎ °³´Â °¢°¢ deoxyribonucleotide¿¡ ºÎÂøµÇ¾î ÀÖ´Â ¿°±âµéÀÌ °áÇÕÀ» ÇÏ¿© µÎ °³ÀÇ »ç½½ÀÌ °áÇյǾî ÀÖ´Â ÀÌÁß³ª¼± ±¸Á¶¸¦ ¸¸µé°Ô µÈ´Ù. 4°¡Áö ¿°±â ¾Æµ¥´ÑÀº Ƽ¹Î°ú °áÇÕÀ» Çϰí, ½ÃÅä½Å°ú °áÇÕÀ» ÇÏ°Ô µÈ´Ù. Áï ´ç°ú ÀλêÀº ±ä »ç½½À» ¸¸µå´Â ¿ªÇÒÀ» ÇÏ°í ±ä »ç½½¿¡ ºÎÂøµÈ ¿°±âµéÀÇ °áÇÕ¿¡ ÀÇÇØ¼ µÎ °³ÀÇ ±ä »ç½½Àº ¼·Î ºÙ¾î¼ ÀÌÁß³ª¼± ±¸Á¶¸¦ ¸¸µç´Ù. DNAÀÇ À¯ÀüÁ¤º¸´Â ¿°±â¿¡ ÀúÀåµÈ´Ù. 4°³ÀÇ ¿°±âÀÇ Á¶ÇÕ°ú ¹è¿ÀÌ À¯ÀüÁ¤º¸¸¦ º¸°üÇÏ´Â ÇϳªÀÇ ¾ÏÈ£ ¿ªÇÒÀ» ÇàÇÏ°Ô µÈ´Ù. |
||
| ¿µ¹® | DNA | ÇÑ±Û | µð¿Á½Ã¸®º¸ÇÙ»ê, µð¿£¿¡ÀÌ |
|---|---|---|---|
| ¼³¸í | Deoxyribonucleic acidÀÇ ¾à¾î. µ¥¿Á½Ã¸®º¸½º¸¦ ±¸¼º¼ººÐÀ¸·Î ÇÏ´Â ÇÙ»ê. À¯ÀüÀÚÀÇ ÈÇÐÀû º»Å·μ ¿°»öü¿¡ Á¸ÀçÇÑ´Ù. µ¥¿Á½Ã¸®º¸½º¿¡ À¯±â¿°±â¿Í ÀλêÀÌ °áÇÕÇÑ ´ºÅ¬·¹¿ÀƼµå(±¸¼º´ÜÀ§)°¡ Æ÷½ºÆ÷µð¿¡½ºÅ׸£°áÇÕ¿¡ ÀÇÇØ ±ä»ç½½ ÁßÇÕü¸¦ Çü¼ºÇϸç, µÎ °³ÀÇ ±ä»ç½½ÀÌ ¼·Î ºñƲ·Á ²¿ÀÎ ³ª¼±±¸Á¶¸¦ ÃëÇÑ´Ù. µð¿Á½Ã¸®º¸´ºÅ¬·¹¿ÀƼµå(deoxyribonucleotide)´Â ¿°±â¿Í ´ç(2'-deoxy-D-riboe)°ú ÀλêÀ¸·Î ÀÌ·ç¾îÁø´Ù. ¿°±â´Â ¾Æµ¥´Ñ(adenine), ±¸¾Æ´Ñ(guanine), Ƽ¹Î(thymine) ¹× ½ÃÅä½Å(cytosine)ÀÇ ³×°¡ÁöÀ̸ç, À̰ÍÀº ´ç¿¡ ºÎÂøµÇ¾î ÀÖ´Ù. ÀÎ»ê ¿ª½Ã ´çÀÇ ÇÑ ºÎºÐ¿¡ ºÎÂøµÇ¾î ÀÖ´Ù. ÀÌ µð¿Á½Ã¸®º¸´ºÅ¬·¹¿ÀƼµåÀÇ ´çÀº ´Ù¸¥ µð¿Á½Ã¸®º¸´ºÅ¬·¹¿ÀƼµåÀÇ ´ç°ú ÀλêÀ» »çÀÌ¿¡ ³õ°í °áÇÕÇÏ°Ô µÇ¾î ÇϳªÀÇ ±ä »ç½½À» Çü¼ºÇÏ°Ô µÈ´Ù. |
||
| G1 | presynthetic gap [phase of cells prior to DNA synthesis] |
|---|---|
| G2 | postsynthetic gap [phase of cells following DNA synthesis] |
| ILP | inadequate luteal phase; insufficiency of luteal phase; interstitial laser photocoagulation; interst... |
| SPIA | solid-phase immunoabsorption; solid-phase immunoassay |
| CSL | cardiolipin synthetic lecithin; corticosteroid liposome |
| Phase I | phase |
|---|---|
| S phase | synthesis phase |
| FSR | fractional synthetic rate |
| S | Synthetic |
| SOF | Synthetic Oviduct Fluid |
IGF-II : insulin like growth factor-IIÀÇ ¾àÀÚ. ¸¹Àº Àå±â¿Í Á¶Á÷¿¡ ÀÛ¿ëÇÏ¿© ´Ü¹é ÇÕ¼º°ú DNA, RNAÀÇ ÇÕ¼ºÀ» Áõ°¡½ÃÄÑ ¼¼Æ÷ÀÇ ¼ö¿Í ¾çÀ» Áõ°¡
| DNA-directed DNA polymerase | <enzyme> DNA-dependent DNA polymerases found in bacteria, animal and plant cells. During the replication process, these enzymes catalyze the addition of deoxyribonucleotide residues to the end of a DNA strand in the presence of DNA as template-primer. They also possess exonuclease activity and therefore function in DNA repair. Chemical name: Deoxynucleoside-triphosphate:DNA deoxynucleotidyltransferase (DNA-directed) Registry number: EC 2.7.7.7 (12 Dec 1998) |
|---|---|
| androgens, synthetic | Compounds obtained by chemical synthesis which possess masculinizing activities, but differ in structure from naturally occurring androgens. (12 Dec 1998) |
| vaccines, synthetic | Small synthetic peptides that mimic surface antigens of pathogens and are immunogenic, or vaccines manufactured with the aid of recombinant DNA techniques. The latter vaccines may also be whole viruses whose nucleic acids have been modified. (12 Dec 1998) |
| genes, synthetic | Biologically functional sequences of DNA chemically synthesised in vitro. (12 Dec 1998) |
| glucocorticoids, synthetic | <chemical> Synthetic chemical compounds which increase gluconeogenesis, raising the concentration of liver glycogen and blood sugar, but differ in structure from naturally occurring glucocorticoids. Pharmacological action: steroidal anti-inflammatory agents, topical anti-inflammatory agents. (12 Dec 1998) |
| resins, synthetic | Polymers of high molecular weight which at some stage are capable of being molded and then harden to form useful components. (12 Dec 1998) |
| mineralocorticoids, synthetic | Synthetic steroids that mimic the activity of the mineralocorticoids obtained from the adrenal cortex, but differ in structure from the naturally occurring mineralocorticoids. (12 Dec 1998) |
| contraceptives, oral, synthetic | Oral contraceptives which owe their effectiveness to synthetic preparations. (12 Dec 1998) |
| contraceptives, postcoital, synthetic | Postcoital contraceptives which owe their effectiveness to synthetic preparations. (12 Dec 1998) |
| progestational hormones, synthetic | Compounds obtained by chemical synthesis that possess progestational activity, but differ in structure from naturally occurring progestational hormones. (12 Dec 1998) |
| prostaglandin endoperoxides, synthetic | Synthetic compounds that are analogs of the naturally occurring prostaglandin endoperoxides and that mimic their pharmacologic and physiologic activities. They are usually more stable than the naturally occurring compounds. (12 Dec 1998) |
| prostaglandins a, synthetic | Analogs or derivatives of prostaglandin a that do not occur naturally in the body. They do not include the product of the chemical synthesis of hormonal pga. (12 Dec 1998) |
| prostaglandins e, synthetic | Analogs or derivatives of prostaglandins e that do not occur naturally in the body. They do not include the product of the chemical synthesis of hormonal pge. (12 Dec 1998) |
| prostaglandins f, synthetic | Analogs or derivatives of prostaglandins f that do not occur naturally in the body. They do not include the product of the chemical synthesis of hormonal pgf. (12 Dec 1998) |
| prostaglandins, synthetic | Compounds obtained by chemical synthesis that are analogs or derivatives of naturally occurring prostaglandins and that have similar activity. (12 Dec 1998) |
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|